Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Clinical Nuclear Medicine
|
March 30, 2022
A Peculiar 18 F-FDG Spinal Uptake Helps Diagnosis and Effective Treatment of Polymyalgia Rheumatica : "The Corset Sign"
Helena Lanzafame, Lucia Zanoni, Vincenzo Allegri, et al.
Cancers
|
April 12, 2022
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature
Pierpaolo Alongi, Riccardo Laudicella, Helena Lanzafame, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 8, 2021
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients
Alfredo Campennì, Rosaria Maddalena Ruggeri, Massimiliano Siracusa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 21, 2023
Oncologic Staging with <sup>68</sup>Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than <sup>18</sup>F-FDG PET/CT
Tristan T Demmert, Kelsey L Pomykala, Helena Lanzafame, et al.
Nuclear Medicine Communications
|
February 24, 2021
BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer
Alfredo Campennì, Rosaria M Ruggeri, Giuseppe Giuffrè, et al.
PET Clinics
|
March 30, 2023
Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma
Rainer Hamacher, Helena Lanzafame, Ilektra A Mavroeidi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 25, 2024
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
John Nikitas, Ethan Lam, Kiara Adame Booker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 9, 2024
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 3, 2025
Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy
Lisa Steinhelfer, Friederike Jungmann, Lukas Endroes, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Clinical Nuclear Medicine
|
March 30, 2022
A Peculiar 18 F-FDG Spinal Uptake Helps Diagnosis and Effective Treatment of Polymyalgia Rheumatica : "The Corset Sign"
Helena Lanzafame, Lucia Zanoni, Vincenzo Allegri, et al.
Cancers
|
April 12, 2022
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature
Pierpaolo Alongi, Riccardo Laudicella, Helena Lanzafame, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
January 8, 2021
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients
Alfredo Campennì, Rosaria Maddalena Ruggeri, Massimiliano Siracusa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 21, 2023
Oncologic Staging with <sup>68</sup>Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than <sup>18</sup>F-FDG PET/CT
Tristan T Demmert, Kelsey L Pomykala, Helena Lanzafame, et al.
Nuclear Medicine Communications
|
February 24, 2021
BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer
Alfredo Campennì, Rosaria M Ruggeri, Giuseppe Giuffrè, et al.
PET Clinics
|
March 30, 2023
Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma
Rainer Hamacher, Helena Lanzafame, Ilektra A Mavroeidi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 25, 2024
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
John Nikitas, Ethan Lam, Kiara Adame Booker, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 9, 2024
<sup>68</sup>Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 19, 2026
<sup>90</sup>Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis
Helena Lanzafame, Ilektra A Mavroeidi, Kim M Pabst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 3, 2025
Multicentric Matched-Pair Analysis of Long-Term Hematotoxicity of Peptide Receptor Radionuclide Therapy in Patients Postsplenectomy
Lisa Steinhelfer, Friederike Jungmann, Lukas Endroes, et al.
Page
of 2